ASM International N.V. buy melinda
Start price
16.01.18
/
50%
€58.54
Target price
19.03.18
€71.00
Performance (%)
5.57%
End price
19.03.18
€61.80
Summary
This prediction ended on 19.03.18 with a price of €61.80. The BUY prediction by melinda finished with a performance of 5.57%. melinda has a follow-up prediction for ASM International N.V. where he still thinks ASM International N.V. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
ASM International N.V. | -10.516% | -10.516% | 69.546% | 129.318% |
iShares Core DAX® | -3.033% | -0.013% | 11.953% | 15.609% |
iShares Nasdaq 100 | -3.554% | -2.546% | 30.128% | 44.540% |
iShares Nikkei 225® | -3.938% | 2.183% | 11.741% | 8.345% |
iShares S&P 500 | -1.517% | -0.882% | 25.752% | 42.388% |
According to melinda what are the pros and cons of ASM International N.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Asm International N.V. diskutieren
SecteurProduits im Zusammenhang mit der Halbleiterindustrie Agenda 18/01 Übersicht
2018.01.16 | 9.45
Bryan Garnier initiierte Abdeckung von ASM International mit einer Empfehlung "buy" und einem inneren Wert ( 'Fair Value') von 71 Euro (+ 23%), unter Hinweis darauf, dass dies OEM für Halbleiter mit einer Führung in ALD-Tool hat
(Vom Mitglied beendet)
Current prediction by melinda for ASM International N.V.
ASM International N.V.
Start price
Target price
Perf. (%)
€577.40
03.03.24
03.03.24
€600.00
03.03.25
03.03.25
17.35%
22:26
22:26
Could be worthwhile Investment >10% per year
Stopped prediction by melinda for ASM International N.V.
ASM International N.V.
Start price
Target price
Perf. (%)
€375.00
13.01.22
13.01.22
€40.00
13.01.23
13.01.23
-22.87%
10.09.22
10.09.22
Could be worthwhile Investment >10% per year
ASM International N.V.
Start price
Target price
Perf. (%)
€60.24
25.04.19
25.04.19
€60.00
26.11.19
26.11.19
0.00%
26.11.19
26.11.19
Could be worthwhile Investment >10% per year